Do analysts recommend ATOS or BNR?

Atossa Genetics currently has a consensus target price of $20.33, suggesting a potential upside of 688.11%. Given Atossa Genetics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Atossa Genetics is more favorable than Burning Rock Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atossa Genetics 2 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.20 Burning Rock Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to ATOS or BNR?

In the previous week, Burning Rock Biotech had 1 more articles in the media than Atossa Genetics. MarketBeat recorded 3 mentions for Burning Rock Biotech and 2 mentions for Atossa Genetics. Atossa Genetics' average media sentiment score of 0.94 beat Burning Rock Biotech's score of 0.63 indicating that Atossa Genetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atossa Genetics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Burning Rock Biotech 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate ATOS or DTSQ?

Atossa Genetics presently has a consensus price target of $20.33, suggesting a potential upside of 688.11%. Given Atossa Genetics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Atossa Genetics is more favorable than DT Cloud Star Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atossa Genetics 2 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.20 DT Cloud Star Acquisition 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher valuation and earnings, ATOS or DTSQ?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Atossa Genetics N/A N/A -$34.77M -$3.11 N/A DT Cloud Star Acquisition N/A N/A N/A N/A N/A

Is ATOS or DTSQ more profitable?

DT Cloud Star Acquisition's return on equity of 0.00% beat Atossa Genetics' return on equity. Company Net Margins Return on Equity Return on Assets Atossa Genetics N/A -102.99% -85.78% DT Cloud Star Acquisition N/A N/A N/A

Does the media refer more to ATOS or DTSQ?

In the previous week, DT Cloud Star Acquisition had 1 more articles in the media than Atossa Genetics. MarketBeat recorded 3 mentions for DT Cloud Star Acquisition and 2 mentions for Atossa Genetics. DT Cloud Star Acquisition's average media sentiment score of 1.07 beat Atossa Genetics' score of 0.94 indicating that DT Cloud Star Acquisition is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atossa Genetics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive DT Cloud Star Acquisition 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, ATOS or KLRS?

Kalaris Therapeutics is trading at a lower price-to-earnings ratio than Atossa Genetics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Atossa Genetics N/A N/A -$34.77M -$3.11 N/A Kalaris Therapeutics N/A N/A -$43.44M -$2.02 N/A

Is ATOS or KLRS more profitable?

Kalaris Therapeutics' return on equity of -71.71% beat Atossa Genetics' return on equity. Company Net Margins Return on Equity Return on Assets Atossa Genetics N/A -102.99% -85.78% Kalaris Therapeutics N/A -71.71% -42.95%

Is ATOS or OTLK more profitable?

Oncobiologics' return on equity of 0.00% beat Atossa Genetics' return on equity. Company Net Margins Return on Equity Return on Assets Atossa Genetics N/A -102.99% -85.78% Oncobiologics N/A N/A -254.82%

Does the media refer more to ATOS or OTLK?

In the previous week, Oncobiologics had 1 more articles in the media than Atossa Genetics. MarketBeat recorded 3 mentions for Oncobiologics and 2 mentions for Atossa Genetics. Atossa Genetics' average media sentiment score of 0.94 beat Oncobiologics' score of 0.67 indicating that Atossa Genetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atossa Genetics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oncobiologics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend ATOS or PCSC?

Atossa Genetics currently has a consensus target price of $20.33, suggesting a potential upside of 688.11%. Given Atossa Genetics' stronger consensus rating and higher probable upside, analysts clearly believe Atossa Genetics is more favorable than Perceptive Capital Solutions. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atossa Genetics 2 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.20 Perceptive Capital Solutions 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, ATOS or PCSC?

Perceptive Capital Solutions is trading at a lower price-to-earnings ratio than Atossa Genetics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Atossa Genetics N/A N/A -$34.77M -$3.11 N/A Perceptive Capital Solutions N/A N/A $840K -$0.06 N/A

Is ATOS or PCSC more profitable?

Perceptive Capital Solutions' return on equity of -2.70% beat Atossa Genetics' return on equity. Company Net Margins Return on Equity Return on Assets Atossa Genetics N/A -102.99% -85.78% Perceptive Capital Solutions N/A -2.70% -0.84%

Atossa Genetics (ATOS) Competitors

$2.58 -0.06 (-2.27%)

As of 08/28/2026 04:00 PM Eastern

Compare

ATOS vs. BNR, DTSQ, KLRS, OTLK, and PCSC

Should you buy Atossa Genetics stock or one of its competitors? Atossa Genetics's main competitors and comparable companies include Burning Rock Biotech (BNR), DT Cloud Star Acquisition (DTSQ), Kalaris Therapeutics (KLRS), Oncobiologics (OTLK), and Perceptive Capital Solutions (PCSC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Atossa Genetics compare to Burning Rock Biotech?

Atossa Genetics (NASDAQ:ATOS) and Burning Rock Biotech (NASDAQ:BNR) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, valuation, profitability, risk, analyst recommendations, media sentiment and institutional ownership.

In the previous week, Burning Rock Biotech had 1 more articles in the media than Atossa Genetics. MarketBeat recorded 3 mentions for Burning Rock Biotech and 2 mentions for Atossa Genetics. Atossa Genetics' average media sentiment score of 0.94 beat Burning Rock Biotech's score of 0.63 indicating that Atossa Genetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atossa Genetics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Burning Rock Biotech	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

12.7% of Atossa Genetics shares are held by institutional investors. Comparatively, 30.0% of Burning Rock Biotech shares are held by institutional investors. 9.8% of Atossa Genetics shares are held by insiders. Comparatively, 30.3% of Burning Rock Biotech shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Burning Rock Biotech has higher revenue and earnings than Atossa Genetics. Burning Rock Biotech is trading at a lower price-to-earnings ratio than Atossa Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atossa Genetics	N/A	N/A	-$34.77M	-$3.11	N/A
Burning Rock Biotech	$514.43M	0.21	-$7.92M	-$0.82	N/A

Atossa Genetics has a beta of 1.29, suggesting that its share price is 29% more volatile than the broader market. Comparatively, Burning Rock Biotech has a beta of 1.34, suggesting that its share price is 34% more volatile than the broader market.

Atossa Genetics currently has a consensus target price of $20.33, suggesting a potential upside of 688.11%. Given Atossa Genetics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Atossa Genetics is more favorable than Burning Rock Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atossa Genetics	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Burning Rock Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Atossa Genetics has a net margin of 0.00% compared to Burning Rock Biotech's net margin of -11.57%. Burning Rock Biotech's return on equity of -10.98% beat Atossa Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atossa Genetics	N/A	-102.99%	-85.78%
Burning Rock Biotech	-11.57%	-10.98%	-7.33%

Summary

Burning Rock Biotech beats Atossa Genetics on 9 of the 15 factors compared between the two stocks.

How does Atossa Genetics compare to DT Cloud Star Acquisition?

Atossa Genetics (NASDAQ:ATOS) and DT Cloud Star Acquisition (NASDAQ:DTSQ) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, dividends, valuation, risk, profitability, earnings and analyst recommendations.

In the previous week, DT Cloud Star Acquisition had 1 more articles in the media than Atossa Genetics. MarketBeat recorded 3 mentions for DT Cloud Star Acquisition and 2 mentions for Atossa Genetics. DT Cloud Star Acquisition's average media sentiment score of 1.07 beat Atossa Genetics' score of 0.94 indicating that DT Cloud Star Acquisition is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atossa Genetics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
DT Cloud Star Acquisition	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

12.7% of Atossa Genetics shares are owned by institutional investors. 9.8% of Atossa Genetics shares are owned by company insiders. Comparatively, 52.9% of DT Cloud Star Acquisition shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Atossa Genetics has a beta of 1.29, meaning that its stock price is 29% more volatile than the broader market. Comparatively, DT Cloud Star Acquisition has a beta of -0.01, meaning that its stock price is 101% less volatile than the broader market.

Atossa Genetics presently has a consensus price target of $20.33, suggesting a potential upside of 688.11%. Given Atossa Genetics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Atossa Genetics is more favorable than DT Cloud Star Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atossa Genetics	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
DT Cloud Star Acquisition	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atossa Genetics	N/A	N/A	-$34.77M	-$3.11	N/A
DT Cloud Star Acquisition	N/A	N/A	N/A	N/A	N/A

DT Cloud Star Acquisition's return on equity of 0.00% beat Atossa Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atossa Genetics	N/A	-102.99%	-85.78%
DT Cloud Star Acquisition	N/A	N/A	N/A

Summary

Atossa Genetics and DT Cloud Star Acquisition tied by winning 5 of the 10 factors compared between the two stocks.

How does Atossa Genetics compare to Kalaris Therapeutics?

Atossa Genetics (NASDAQ:ATOS) and Kalaris Therapeutics (NASDAQ:KLRS) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, media sentiment, earnings, analyst recommendations and dividends.

Kalaris Therapeutics is trading at a lower price-to-earnings ratio than Atossa Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atossa Genetics	N/A	N/A	-$34.77M	-$3.11	N/A
Kalaris Therapeutics	N/A	N/A	-$43.44M	-$2.02	N/A

Atossa Genetics has a beta of 1.29, meaning that its stock price is 29% more volatile than the broader market. Comparatively, Kalaris Therapeutics has a beta of 0.2, meaning that its stock price is 80% less volatile than the broader market.

Kalaris Therapeutics' return on equity of -71.71% beat Atossa Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atossa Genetics	N/A	-102.99%	-85.78%
Kalaris Therapeutics	N/A	-71.71%	-42.95%

In the previous week, Atossa Genetics had 1 more articles in the media than Kalaris Therapeutics. MarketBeat recorded 2 mentions for Atossa Genetics and 1 mentions for Kalaris Therapeutics. Kalaris Therapeutics' average media sentiment score of 1.87 beat Atossa Genetics' score of 0.94 indicating that Kalaris Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Atossa Genetics	Positive
Kalaris Therapeutics	Very Positive

Atossa Genetics currently has a consensus target price of $20.33, suggesting a potential upside of 688.11%. Kalaris Therapeutics has a consensus target price of $18.75, suggesting a potential upside of 365.26%. Given Atossa Genetics' higher probable upside, research analysts clearly believe Atossa Genetics is more favorable than Kalaris Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atossa Genetics	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Kalaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

12.7% of Atossa Genetics shares are owned by institutional investors. Comparatively, 66.1% of Kalaris Therapeutics shares are owned by institutional investors. 9.8% of Atossa Genetics shares are owned by insiders. Comparatively, 68.1% of Kalaris Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Kalaris Therapeutics beats Atossa Genetics on 9 of the 14 factors compared between the two stocks.

How does Atossa Genetics compare to Oncobiologics?

Atossa Genetics (NASDAQ:ATOS) and Oncobiologics (NASDAQ:OTLK) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, risk, dividends, profitability, analyst recommendations, earnings and valuation.

Oncobiologics' return on equity of 0.00% beat Atossa Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atossa Genetics	N/A	-102.99%	-85.78%
Oncobiologics	N/A	N/A	-254.82%

Atossa Genetics has a beta of 1.29, meaning that its share price is 29% more volatile than the broader market. Comparatively, Oncobiologics has a beta of 0.82, meaning that its share price is 18% less volatile than the broader market.

In the previous week, Oncobiologics had 1 more articles in the media than Atossa Genetics. MarketBeat recorded 3 mentions for Oncobiologics and 2 mentions for Atossa Genetics. Atossa Genetics' average media sentiment score of 0.94 beat Oncobiologics' score of 0.67 indicating that Atossa Genetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atossa Genetics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oncobiologics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

12.7% of Atossa Genetics shares are owned by institutional investors. Comparatively, 11.2% of Oncobiologics shares are owned by institutional investors. 9.8% of Atossa Genetics shares are owned by company insiders. Comparatively, 1.8% of Oncobiologics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Atossa Genetics has higher revenue and earnings than Oncobiologics. Oncobiologics is trading at a lower price-to-earnings ratio than Atossa Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atossa Genetics	N/A	N/A	-$34.77M	-$3.11	N/A
Oncobiologics	-$1.16M	-82.36	-$62.42M	-$0.77	N/A

Atossa Genetics presently has a consensus price target of $20.33, suggesting a potential upside of 688.11%. Oncobiologics has a consensus price target of $5.20, suggesting a potential upside of 706.33%. Given Oncobiologics' higher possible upside, analysts plainly believe Oncobiologics is more favorable than Atossa Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atossa Genetics	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Oncobiologics	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Summary

Atossa Genetics beats Oncobiologics on 9 of the 13 factors compared between the two stocks.

How does Atossa Genetics compare to Perceptive Capital Solutions?

Atossa Genetics (NASDAQ:ATOS) and Perceptive Capital Solutions (NASDAQ:PCSC) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, profitability, media sentiment, analyst recommendations, earnings and institutional ownership.

Atossa Genetics currently has a consensus target price of $20.33, suggesting a potential upside of 688.11%. Given Atossa Genetics' stronger consensus rating and higher probable upside, analysts clearly believe Atossa Genetics is more favorable than Perceptive Capital Solutions.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atossa Genetics	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Perceptive Capital Solutions	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Atossa Genetics has a beta of 1.29, indicating that its stock price is 29% more volatile than the broader market. Comparatively, Perceptive Capital Solutions has a beta of 0.36, indicating that its stock price is 64% less volatile than the broader market.

Perceptive Capital Solutions' return on equity of -2.70% beat Atossa Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atossa Genetics	N/A	-102.99%	-85.78%
Perceptive Capital Solutions	N/A	-2.70%	-0.84%

In the previous week, Atossa Genetics had 2 more articles in the media than Perceptive Capital Solutions. MarketBeat recorded 2 mentions for Atossa Genetics and 0 mentions for Perceptive Capital Solutions. Atossa Genetics' average media sentiment score of 0.94 beat Perceptive Capital Solutions' score of 0.00 indicating that Atossa Genetics is being referred to more favorably in the media.

Company	Overall Sentiment
Atossa Genetics	Positive
Perceptive Capital Solutions	Neutral

Perceptive Capital Solutions is trading at a lower price-to-earnings ratio than Atossa Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atossa Genetics	N/A	N/A	-$34.77M	-$3.11	N/A
Perceptive Capital Solutions	N/A	N/A	$840K	-$0.06	N/A

12.7% of Atossa Genetics shares are owned by institutional investors. 9.8% of Atossa Genetics shares are owned by company insiders. Comparatively, 22.1% of Perceptive Capital Solutions shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Atossa Genetics beats Perceptive Capital Solutions on 8 of the 13 factors compared between the two stocks.

Get Atossa Genetics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ATOS vs. The Competition

Export

Metric	Atossa Genetics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$25.75M	$3.93B	$7.20B	$12.90B
Dividend Yield	N/A	3.61%	2.54%	11.28%
P/E Ratio	-0.83	11.62	273.16	25.45
Price / Sales	N/A	1,291.80	604.48	76.58
Price / Cash	N/A	106.39	76.74	53.00
Price / Book	0.96	16.53	12.98	6.14
Net Income	-$34.77M	-$22.80M	$3.48B	$348.86M
7 Day Performance	1.57%	-0.31%	0.13%	-0.80%
1 Month Performance	17.81%	9.80%	7.08%	4.13%
1 Year Performance	-77.45%	55.66%	24.67%	15.17%

Atossa Genetics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ATOS Atossa Genetics	2.0963 of 5 stars	$2.58 -2.3%	$20.33 +688.1%	-77.5%	$25.75M	N/A	N/A	8
BNR Burning Rock Biotech	0.7697 of 5 stars	$9.64 -6.6%	N/A	+19.1%	$101.41M	$77.16M	N/A	1,390	Upcoming Earnings Analyst Downgrade Gap Down
DTSQ DT Cloud Star Acquisition	1.8842 of 5 stars	$11.36 +0.2%	N/A	+8.5%	$101.06M	N/A	N/A	N/A	Positive News Short Interest Decrease
KLRS Kalaris Therapeutics	2.4885 of 5 stars	$4.11 +0.1%	$18.75 +356.8%	-1.2%	$100.81M	N/A	N/A	110
OTLK Oncobiologics	3.6659 of 5 stars	$0.66 +8.5%	$4.65 +603.5%	-24.2%	$98.07M	$1.35M	N/A	20

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ATOS) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Atossa Genetics (ATOS) Competitors

ATOS vs. BNR, DTSQ, KLRS, OTLK, and PCSC

How does Atossa Genetics compare to Burning Rock Biotech?

Summary

How does Atossa Genetics compare to DT Cloud Star Acquisition?

Summary

How does Atossa Genetics compare to Kalaris Therapeutics?

Summary

How does Atossa Genetics compare to Oncobiologics?

Summary

How does Atossa Genetics compare to Perceptive Capital Solutions?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATOS vs. The Competition

Atossa Genetics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Atossa Genetics (ATOS) Competitors

ATOS vs. BNR, DTSQ, KLRS, OTLK, and PCSC

How does Atossa Genetics compare to Burning Rock Biotech?

Does the media refer more to ATOS or BNR?

Do insiders and institutionals hold more shares of ATOS or BNR?

Which has higher earnings & valuation, ATOS or BNR?

Which has more risk and volatility, ATOS or BNR?

Do analysts recommend ATOS or BNR?

Is ATOS or BNR more profitable?

Summary

How does Atossa Genetics compare to DT Cloud Star Acquisition?

Does the media refer more to ATOS or DTSQ?

Do insiders & institutionals hold more shares of ATOS or DTSQ?

Which has more volatility & risk, ATOS or DTSQ?

Do analysts rate ATOS or DTSQ?

Which has higher valuation and earnings, ATOS or DTSQ?

Is ATOS or DTSQ more profitable?

Summary

How does Atossa Genetics compare to Kalaris Therapeutics?

Which has preferable earnings & valuation, ATOS or KLRS?

Which has more volatility and risk, ATOS or KLRS?

Is ATOS or KLRS more profitable?

Does the media refer more to ATOS or KLRS?

Do analysts rate ATOS or KLRS?

Do insiders and institutionals hold more shares of ATOS or KLRS?

Summary

How does Atossa Genetics compare to Oncobiologics?

Is ATOS or OTLK more profitable?

Which has more risk & volatility, ATOS or OTLK?

Does the media refer more to ATOS or OTLK?

Do institutionals & insiders hold more shares of ATOS or OTLK?

Which has stronger valuation & earnings, ATOS or OTLK?

Do analysts rate ATOS or OTLK?

Summary

How does Atossa Genetics compare to Perceptive Capital Solutions?

Do analysts recommend ATOS or PCSC?

Which has more volatility & risk, ATOS or PCSC?

Is ATOS or PCSC more profitable?

Does the media prefer ATOS or PCSC?

Which has better earnings and valuation, ATOS or PCSC?

Do institutionals and insiders hold more shares of ATOS or PCSC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATOS vs. The Competition

Atossa Genetics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools